Diagnostic Associations in a Large and Consecutively Identified Population Positive for Anti-SSA And/or Anti-SSB: the Range of Associated Diseases Differs According to the Detailed Serotype

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2002 Nov 14

PMID 12429541

Citations 17

Authors

I Peene

L Meheus

E M Veys

F de Keyser

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the diagnostic distribution in a consecutive anti-SSA and/or anti-SSB positive population.

Methods: A total of 15 937 serum samples from 10 550 consecutive patients were analysed for antinuclear antibodies (ANAs) on HEp-2 cells. Serum samples positive for ANAs were analysed by immunodiffusion and line immunoassay with recombinant SSA-Ro52, natural SSA-Ro60, and recombinant SSB.

Results: Among ANA positive patients in whom clinical information was available, 181 consecutive patients with anti-SSA and/or anti-SSB antibodies were identified, Disease associations were systemic lupus erythematosus (SLE) (45.3%), primary Sjögren's syndrome (pSS) (14.4%), scleroderma (8.8%), RA (7.7%), cutaneous lupus (7.7%), and dermatomyositis (2.2%). The ratio of diagnoses differed according to the anti-SSA/anti-SSB serotype. Scleroderma and dermatomyositis were enriched among mono-Ro52 reactive serum samples (34.2% and 10.5% respectively). Single reactivity towards Ro60 or anti-Ro60 with anti-Ro52 predisposed for SLE (80.0% and 52.2% respectively). Triple reactivity towards Ro52, Ro60, and SSB was primarily linked with SLE (55.8%) followed by pSS (20.9%). Anti-SSA on immunodiffusion increased the chance for SLE (62.8%), whereas isolated anti-SSB reactivity on immunodiffusion was less indicative for SLE (14.3%) and predisposed more for cutaneous lupus (23.8%) and pSS (33.3%).

Conclusion: The diagnostic range associated with anti-SSA or anti-SSB reactivity differs significantly according to the detailed serotype defined by line immunoassay and immunodiffusion.

Citing Articles

Antinuclear antibody (ANA) positivity pattern by line immunoassay in a hospital from eastern India: Update from a laboratory perspective.

Banerjee A, Ranjan A, Kumar M, Kumar S, Bansal A, Mahto M J Family Med Prim Care. 2024; 13(4):1254-1261.

PMID: 38827670 PMC: 11141993. DOI: 10.4103/jfmpc.jfmpc_1170_23.

Current state of technologies and recognition of anti-SSA/Ro antibodies in China: A multi-center study.

Chen Y, Hu C, Peng L, Wang C, Zhao Y, Zhang W J Clin Lab Anal. 2021; 35(12):e24045.

PMID: 34674312 PMC: 8649342. DOI: 10.1002/jcla.24045.

Sicca syndrome in the same family - the importance of anti-Ro60, anti-Ro52 and anti-La antibody profiling in Sjögren's syndrome.

Koszarny A, Majdan M Reumatologia. 2021; 59(4):260-264.

PMID: 34538957 PMC: 8436791. DOI: 10.5114/reum.2021.108653.

Ultrasonography predicts the results of labial salivary gland biopsy in patients with suspected Sjögren's syndrome: a matrix risk model.

Mo Y, Hao S, Li Q, Liang J, Luo Y, Lan Y Ther Adv Musculoskelet Dis. 2021; 13:1759720X211010592.

PMID: 33995602 PMC: 8071977. DOI: 10.1177/1759720X211010592.

Clinical influences of anticentromere antibody on primary Sjögren's syndrome in a prospective Korean cohort.

Park Y, Lee J, Koh J, Choe J, Sung Y, Lee S Korean J Intern Med. 2020; 36(6):1492-1503.

PMID: 32829574 PMC: 8588972. DOI: 10.3904/kjim.2020.146.

References

Brouwer R, Hengstman G, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A . Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001; 60(2):116-23. PMC: 1753477. DOI: 10.1136/ard.60.2.116. View

Meheus L, van Venrooij W, Wiik A, Charles P, Tzioufas A, Meyer O . Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol. 1999; 17(2):205-14. View

Peene I, Meheus L, Veys E, de Keyser F . Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis. 2001; 60(12):1131-6. PMC: 1753451. DOI: 10.1136/ard.60.12.1131. View

. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5):581-90. DOI: 10.1002/art.1780230510. View

Tan E, Cohen A, Fries J, MASI A, McShane D, Rothfield N . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11):1271-7. DOI: 10.1002/art.1780251101. View

Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315-24. DOI: 10.1002/art.1780310302. View

Slobbe R, Pruijn G, Damen W, Van Der Kemp J, van Venrooij W . Detection and occurrence of the 60- and 52-kD Ro (SS-A) antigens and of autoantibodies against these proteins. Clin Exp Immunol. 1991; 86(1):99-105. PMC: 1554155. DOI: 10.1111/j.1365-2249.1991.tb05780.x. View

Vitali C, Bombardieri S, Moutsopoulos H, BALESTRIERI G, Bencivelli W, Bernstein R . Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993; 36(3):340-7. DOI: 10.1002/art.1780360309. View

Ben-Chetrit E . The molecular basis of the SSA/Ro antigens and the clinical significance of their autoantibodies. Br J Rheumatol. 1993; 32(5):396-402. DOI: 10.1093/rheumatology/32.5.396. View

10.

Kelekar A, Saitta M, Keene J . Molecular composition of Ro small ribonucleoprotein complexes in human cells. Intracellular localization of the 60- and 52-kD proteins. J Clin Invest. 1994; 93(4):1637-44. PMC: 294201. DOI: 10.1172/JCI117145. View

11.

Lopez-Longo F, Rodriguez-Mahou M, Escalona M, Perez T, Monteagudo I, Sanchez-Atrio A . Heterogeneity of the anti-Ro(SSA) response in rheumatic diseases. J Rheumatol. 1994; 21(8):1450-6. View

12.

Boire G, Gendron M, Monast N, Bastin B, Menard H . Purification of antigenically intact Ro ribonucleoproteins; biochemical and immunological evidence that the 52-kD protein is not a Ro protein. Clin Exp Immunol. 1995; 100(3):489-98. PMC: 1534484. DOI: 10.1111/j.1365-2249.1995.tb03728.x. View

13.

Slater C, Davis R, Shmerling R . Antinuclear antibody testing. A study of clinical utility. Arch Intern Med. 1996; 156(13):1421-5. View

14.

Zimmermann C, Smolen J, Graninger W, Petera P, Fabini G, Hassfeld W . Fine specificity of anti-Ro(SSA) autoantibodies and clinical manifestations in patients with systemic lupus erythematosus. J Rheumatol. 1996; 23(11):1897-903. View

15.

McCauliffe D, Wang L, Satoh M, Reeves W, Small D . Recombinant 52 kDa Ro(SSA) ELISA detects autoantibodies in Sjögren's syndrome sera that go undetected by conventional serologic assays. J Rheumatol. 1997; 24(5):860-6. View

16.

Rutjes S, Vree Egberts W, Jongen P, van den Hoogen F, Pruijn G, van Venrooij W . Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol. 1997; 109(1):32-40. PMC: 1904727. DOI: 10.1046/j.1365-2249.1997.4081308.x. View

17.

Emlen W, ONeill L . Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 1997; 40(9):1612-8. DOI: 10.1002/art.1780400910. View

18.

Targoff I, Miller F, Medsger Jr T, Oddis C . Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1998; 9(6):527-35. DOI: 10.1097/00002281-199711000-00008. View

19.

Scofield R, Farris A, Horsfall A, Harley J . Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. Arthritis Rheum. 1999; 42(2):199-209. DOI: 10.1002/1529-0131(199902)42:2<199::AID-ANR1>3.0.CO;2-1. View

20.

FRANK M, McCubbin V, Trieu E, Wu Y, Isenberg D, Targoff I . The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun. 1999; 12(2):137-42. DOI: 10.1006/jaut.1998.0265. View